Medical diagnostics – 55% of total Amersham sales
Pharmaceutical products used during medical scanning procedures to enhance images and provide information about the structure and functioning of organs, tissues and molecules in the body, for early, accurate diagnosis and management of heart disease, circulatory disorders, lung disease, brain disease and cancer.
Therapy products – 4% of total Amersham sales
Products using radioactive isotopes for the treatment of cancer.
Performance 2002
Sales £948 million, up 8%	Operating profit £256 million, up 9%	R&D expenditure £95 million, up 14%	Employees 5,300

Key products

	Myoview™(kit for preparation of 99mTc tetrafosmin) Sales £133 million, up 26% Our fastest-growing medical diagnostic product, this radio-pharmaceutical imaging agent is used for visualising blood flow to the heart, and may also be used in breast tumour imaging. Patents to 2009-2010.		Visipaque™ (iodixanol) Sales £91 million, up 18% An advanced non-ionic X-ray/CT (computed tomography) product for the diagnosis of coronary artery disease and to aid in stent placement, whose isotonic formulation provides an extra margin of safety and patient comfort. Patents to 2008-2011.
	Optison™ (human albumin microspheres containing perflutren) The leading ultrasound product for the emerging market of contrast-enhanced ultrasound, for visualising the borders of the heart muscle. Patents to 2012-2013.		Research platform Imanet™ Imanet is an expanding network of imaging research centres where Amersham Health works in collaboration with the world’s top pharmaceutical companies. It uses innovative imaging solutions to accelerate drug discovery and development, and to create new molecular diagnostics that will enable physicians, in the future, to more accurately predict and diagnose disease and to tailor treatment accordingly.
	Omniscan™ (gadodiamide) Sales £96 million, up 17% Our leading product for MRI (magnetic resonance imaging), primarily used for imaging the central nervous system (brain tumours, stroke, spinal lesions); use being extended to cardiovascular disease. Patents to 2007-2009.		Omnipaque™ (iohexol) Sales £222 million, up 6% A non-ionic X-ray/CT diagnostic, launched 20 years ago and still the world’s bestselling diagnostic imaging product for a wide range of indications in cardiology, neurology and oncology. Off-patent.
	DaTSCAN™ (ioflupane I123) A molecular diagnostic radiopharmaceutical, this is the first product that enables an objective diagnosis of Parkinson’s disease and related syndromes. Marketed only in Europe. Patents to 2012.		Brachytherapy products Our leading line of radioactive iodine and palladium seed products – OncoSeed™, Rapid Strand™, EchoSeed™, TheraSeed™ – implanted in the prostate gland to treat prostate cancer.